Literature DB >> 28122798

Pituitary acromegaly: not one disease.

Sylvia L Asa1, Walter Kucharczyk2, Shereen Ezzat3.   

Abstract

Acromegaly has traditionally been regarded as a monomorphous disorder resulting from a benign pituitary adenoma. Increasing evidence, however, is highlighting that this disorder is associated with a spectrum of morphologically distinct pituitary tumors with variable clinical, biochemical and radiologic features and differing therapeutic outcomes that are attributed to different genetic and epigenetic changes. These data underscore the need for developing a more refined clinicopathological risk stratification system and implementing personalized targeted therapeutic approaches.
© 2017 Society for Endocrinology.

Entities:  

Keywords:  acromegaly; biomarkers; pathology; pituitary tumors; radiology

Mesh:

Year:  2017        PMID: 28122798     DOI: 10.1530/ERC-16-0496

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  8 in total

1.  Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.

Authors:  Ozgur Mete; Omalkhaire M Alshaikh; Amber Cintosun; Shereen Ezzat; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2018-12       Impact factor: 3.943

Review 2.  Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?

Authors:  Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2021-01-12       Impact factor: 3.943

3.  Quantitative proteomics revealed the molecular characteristics of distinct types of granulated somatotroph adenomas.

Authors:  Yifan Tang; Tao Xie; Silin Wu; Qiaoqiao Yang; Tengfei Liu; Chen Li; Shuang Liu; Zhiyong Shao; Xiaobiao Zhang
Journal:  Endocrine       Date:  2021-05-27       Impact factor: 3.633

Review 4.  Overview of the 2017 WHO Classification of Pituitary Tumors.

Authors:  Ozgur Mete; M Beatriz Lopes
Journal:  Endocr Pathol       Date:  2017-09       Impact factor: 3.943

Review 5.  Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification.

Authors:  Ashley B Grossman; Shereen Ezzat; Sylvia L Asa; Ozgur Mete; Michael D Cusimano; Ian E McCutcheon; Arie Perry; Shozo Yamada; Hiroshi Nishioka; Olivera Casar-Borota; Silvia Uccella; Stefano La Rosa
Journal:  Mod Pathol       Date:  2021-05-21       Impact factor: 7.842

Review 6.  The Clinicopathological Spectrum of Acromegaly.

Authors:  Amit Akirov; Sylvia L Asa; Lama Amer; Ilan Shimon; Shereen Ezzat
Journal:  J Clin Med       Date:  2019-11-13       Impact factor: 4.241

7.  Work disability and its determinants in patients with pituitary tumor-related disease.

Authors:  Daniel J Lobatto; Anath N V Steffens; Amir H Zamanipoor Najafabadi; Cornelie D Andela; Alberto M Pereira; Wilbert B van den Hout; Wilco C Peul; Thea P M Vliet Vlieland; Nienke R Biermasz; Wouter R van Furth
Journal:  Pituitary       Date:  2018-12       Impact factor: 4.107

Review 8.  Pasireotide in the Personalized Treatment of Acromegaly.

Authors:  Manel Puig-Domingo; Ignacio Bernabéu; Antonio Picó; Betina Biagetti; Joan Gil; Cristina Alvarez-Escolá; Mireia Jordà; Montserrat Marques-Pamies; Berta Soldevila; María-Angeles Gálvez; Rosa Cámara; Javier Aller; Cristina Lamas; Mónica Marazuela
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-16       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.